BiotechTube
EpiEndo Pharmaceuticals

EpiEndo Pharmaceuticals

Reykjavik, Europe - Other· Est.
epiendo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4M

Overview

EpiEndo Pharmaceuticals is developing a novel, first-in-class oral therapy for chronic obstructive pulmonary disease (COPD), a leading global cause of death. Its lead asset, glasmacinal, is a non-antibiotic macrolide (Barriolide™) that aims to reduce exacerbations by modulating the host defense response and inflammation, addressing a key limitation of chronic antibiotic use. Founded in 2016, the company is clinical-stage, backed by a strong scientific advisory board, and recently secured €9 million in convertible bond funding to advance development. EpiEndo targets a significant unmet need in a multi-billion dollar market with a potentially safer, long-term oral treatment option.

Chronic Obstructive Pulmonary Disease (COPD)Chronic Respiratory Diseases

Technology Platform

Barriolides™: a proprietary class of non-antibiotic macrolides designed to enhance host defense response and provide anti-inflammatory effects in the respiratory tract without promoting antimicrobial resistance.

Funding History

2
Total raised:$4M
Seed$3.2M
Grant$800K

Opportunities

Glasmacinal addresses a massive unmet need in COPD by offering a first-in-class, oral, non-antibiotic therapy aimed at preventing exacerbations, targeting a multi-billion dollar market with limited competition in its mechanistic class.
The Barriolide™ platform also shows preclinical promise for expansion into other chronic inflammatory diseases, such as ulcerative colitis, providing potential for pipeline diversification.

Risk Factors

The lead program faces significant clinical development risk, as it must prove efficacy in preventing COPD exacerbations in patient trials.
As a private, pre-revenue company, EpiEndo is dependent on future fundraising in a challenging capital environment, and it will eventually face intense competition from established inhaled therapies and biologics in the crowded respiratory market.

Competitive Landscape

EpiEndo competes in the large and competitive COPD market dominated by inhaled bronchodilators/corticosteroids (e.g., GSK, AstraZeneca) and targeted biologics for eosinophilic-driven disease. Its primary differentiation is its oral, non-antibiotic macrolide mechanism focused on host defense. It indirectly competes with chronic, off-label azithromycin use but aims to supersede it by eliminating the AMR risk.

More companies in Europe - Other →